Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)

Part of paid clinical trials in Springfield, Illinois.

Sponsor
Southern Illinois University
Study ID
NCT00304278
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Erlotinib (Tarceva) — DRUG
    150 mg daily X 7 weeks
  • Intra-arterial Cisplatin (PLAT) — DRUG
    1 dose (150 mg/sq) per week X 4 weeks
  • Radiation Therapy (RAD) — RADIATION
    5 days per week X 7 weeks

Study Details

The purpose of this study is to determine the safety and effectiveness of treatment with Tarceva (Erlotinib) and RADPLAT (RADiation and intraarterial cisPLATin) for patients with Head and Neck cancer

Key Dates

First listed
Mar 17, 2006
Start date
Mar 31, 2006
Status verified
May 2026
Primary completion
May 31, 2015
Completion
Dec 31, 2015

Study Design

Enrollment
21 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: RADPLAT and Tarceva
    All patients will receive RADPLAT and Tarceva: Drug: Erlotinib (Tarceva) 150 mg daily X 7 weeks Other Names: Tarceva Drug: Intra-arterial Cisplatin (PLAT) 1 dose (150 mg/sq) per week X 4 weeks Other Names: Cisplatin Radiation: Radiation Therapy (RAD) 5 days per week X 7 weeks

Primary Outcome Measure

Number of Participants With Complete and Partial Response Using RECIST Criteria [ Time Frame: 17 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Simmons Cooper Cancer Institute/SIU School of MedicineSpringfieldIllinois62702-

Find similar trials in Springfield, IL

By condition
Head and neck cancer
By specialty
OncologyENT
By research site
Simmons Cooper Cancer Institute/SIU School of Medicine· Springfield, IL

Related Studies